Comprehensive genomic profiling liquid biopsy trends in clinical trials

Tuesday, 14 July 2020

Available On Demand

Your details:

Email *

* Required

First Name *

* Required

Last Name *

* Required

Job Function *

* Required

Company *

* Required

Country *

* Required

Yes, please email me from time to time about Springer Nature programs, products or services (tick to consent). You can withdraw consent at any time by clicking on the unsubscribe link at the bottom of these emails. * Required

Yes, please contact me from time to time about the sponsor’s respective programs, products or services (tick to consent). You can withdraw consent at any time by contacting the sponsor. * Required

Yes, please contact me from time to time about Illumina, Inc. and its affiliates’ (“Illumina”) respective programs (including webinars, seminars and conferences), products and services (tick to consent). You can unsubscribe from receiving these marketing communications from Illumina at any time by visiting this page * Required

By registering here, you agree that we can contact you to provide you with information about this webcast and your registration details will be seen by Springer Nature and the sponsor. We will not otherwise disclose your personal data to anyone else unless we have your permission as detailed in our Privacy Policy. Terms and conditions can be viewed here. *

I Agree * Required

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Overview

If you’ve already registered, please click here to log in to the webcast

Comprehensive Genomic Profiling (CGP) allows biomedical laboratories to consolidate individual biomarkers into a single NGS assay. CGP testing started from minimal amounts of FFPE tissue and is now leveraging liquid biopsy to facilitate sample collection while decreasing the need for invasive tissue biopsy procedures.

Choosing adequate panel content, combined with sophisticated bioinformatics solutions, allows users to detect variants at very low variant allele frequencies, making the assay compatible for biomarker development programs and clinical trial use.

In this webcast, the speaker will help researchers to determine workflow and bioinformatics considerations when consolidating independent biomarkers into a panel that enables CGP from liquid biopsy samples in translational research.

Discover:

Factors contributing to the trend of CGP testing from liquid biopsy samples in clinical trials
Workflow considerations before selecting a liquid biopsy CGP assay
The impact of the bioinformatics solution used to detect low frequency variants to meet the needs of translational researchers

This webcast has been produced for Illumina, Inc by Nature Research Custom Media. The sponsor retains sole responsibility for content. About this content.

Presenters

Robin Harrington, M.S.

Research Associate, Molecular Characterization Laboratory (MoCha)
Frederick National Laboratory for Cancer Research
View Biography

Moderator: Sarah Hiddleston

Science Journalist
Nature Research Custom Media
View Biography

WorkCast Online Event & Presentation Platform